Navigation Links
Agendia Launches TargetPrint(R) for Breast Cancer Patients
Date:9/4/2008


Optimizing Patient Identification for Targeted Therapies

That Ensure Benefits of Personalized Treatment HUNTINGTON BEACH, Calif., and AMSTERDAM, Netherlands, Sept. 4 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint(R), a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the estrogen receptor (ER), progesterone receptor (PR) and Human Epidermal growth factor Receptor 2 (HER2) in breast cancer tumor biopsies. The accurate measurement of these receptors is of paramount importance in planning treatment of breast cancer patients after surgery and assists physicians and patients in making informed treatment decisions. TargetPrint runs on Agendia's new High Density Chip, which received market clearance last month (August 2008) from the U.S. Food and Drug Administration (FDA).

"Currently available targeted therapies, such as hormone treatments, can have a huge impact on the survival and quality of life of a significant number of breast cancer patients," said Bernhard Sixt, Ph.D., president and chief executive officer of Agendia. "TargetPrint will play a key role in defining which patients are most likely to benefit from these treatments."

"The test's results give a precise molecular read-out of prognostic parameters for breast cancer and provide physicians and patients with reliable guidance on the most suitable treatment for each individual patient," said Richard A. Bender, MD, FACP, chief medical officer of Agendia. "In the near future, it is our plan to add information on a wider range of drug targets to TargetPrint and clinically validate these with key customers."

Agendia will present clinical data on TargetPrint at The 2008 Breast Cancer Symposium which is co-sponsored by the American Society of Clinical Oncology (ASCO) and will be held in Washington, DC from September 5-7, 2008. TargetPrint is processed at Agendia's Clinical Laboratory Improvement Amendments (CLIA) certified and the College of American Pathology (CAP) accredited laboratory.

About Agendia

Agendia is a world leader in molecular cancer diagnostics. The company markets four products based on its breakthrough platform for tumor gene expression profiling and has several new diagnostic tests under development. Agendia was the first company to receive FDA clearance for a breast cancer test, MammaPrint(R), that predicts the risk of breast cancer recurrence. In addition, the company collaborates with pharma companies to develop highly effective personalized drugs in the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands. For more information on Agendia, please visit http://www.agendia.com.

MEDIA CONTACTS

U.S. Media Contact: EU and non-U.S. Media:

Kelly Connor Hans Herklots

Vice President Head Corporate Communications

Ogilvy Public Relations Worldwide Agendia

+1.212.880.5328 Office +31.20.462.1557 Office

+1.609.221.5785 Mobile +31.620.083.509 Mobile

Kelly.connor@ogilvypr.com hans.herklots@agendia.com


'/>"/>
SOURCE Agendia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Aon eSolutions Launches Clinical Trials Module
2. Landmark HIV/AIDS Publication Launches at International AIDS Society Conference in Mexico City
3. Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format
4. Impliant Launches Less-Invasive Version of Patented TOPS(TM) Spine System
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO08
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. BASF Officially Launches the Collaborative Advanced Research Initiative at Harvard University
9. The COSHAR Foundation Launches National Childhood Immunization Awareness Campaign During National Infant Immunization Week (April 19-26)
10. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... May 25, 2016 Digital Health Dialog, ... it by the US Patent and Trademark Office ... includes proprietary processes for electronic opt-­in and processing ... wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for individuals ...
(Date:5/25/2016)... , May 25, 2016 ... the precision of circulating tumour DNA (ctDNA) analysis ... the appointment of Professor Clive Morris ... leadership across the clinical development programme, scientific collaborations, ... help deliver significant improvements in clinical outcomes for ...
(Date:5/24/2016)... 2016 Niederländische Chirurgen haben ... es Ärzten erlaubt, ihre Expertise weltweit zu teilen ... Live Streaming mit einer Instant-Messaging-Funktion und der Möglichkeit, ... in Europa, Afrika, Asien und den ... Plattform registriert. Information und Weiterbildung   ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in the health care ... leaders in the nursing and health care industry. It also provides insight to the ... University. , As the nursing industry is coming out of one of the ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of certified ... industries. Aside from its GMP accreditation, Validation Center is also a registered authority ... services and staff. , Validation Center is ISO17025 accredited and only offers its ...
(Date:5/26/2016)... ... 2016 , ... There are many ways to cook a hot dog, but ... Americans prefer their dogs straight off the grill. Of the 90 percent of Americans ... to cook a hot dog, far outpacing other cooking methods such as steaming (12 ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
Breaking Medicine News(10 mins):